Vevye + Flarex for Dry Eye Syndrome

(FLARE-VEV Trial)

This trial examines the safety and effectiveness of combining two eye drops, Vevye and Flarex, for treating moderate to severe dry eye disease. Participants will apply Vevye twice daily and Flarex four times daily for one month. This trial may suit adults experiencing moderate to severe dry eyes. As a Phase 4 trial, this research aims to understand how the already FDA-approved and effective treatment benefits a broader range of patients.

The trial does not specify if you need to stop taking your current medications. However, if you are using topical eye medications or systemic medications that cause dry eye, you may need to stop those before participating.

Research has shown that Vevye, an eye drop solution, is generally safe for long-term use. In studies, most participants tolerated it well, with only 8% experiencing mild reactions like discomfort at the application site. A small number, about 3%, noticed a temporary decrease in vision, but this effect did not persist.

Flarex, another type of eye drop, also maintains a good safety record, though a few important considerations exist. While effective, long-term use might increase eye pressure, potentially leading to glaucoma, a condition that can harm the eye's nerve. It might also cause cataracts, which cloud the eye's lens. However, these issues are more likely with very long-term use, and doctors closely monitor these risks.

Unlike most treatments for dry eye syndrome that typically focus on lubrication or inflammation reduction, Vevye + Flarex offers a unique combination approach. Vevye contains cyclosporine, an active ingredient that helps increase tear production by modulating the immune response, while Flarex, with fluorometholone acetate, targets inflammation directly. Researchers are excited because this dual-action therapy may provide more comprehensive relief, addressing both tear production and inflammation simultaneously, potentially leading to faster and more effective symptom improvement.

Research has shown that Vevye, an eye drop containing cyclosporine, effectively treats dry eye disease. It reduced eye dryness and improved blurry vision for many patients in just 29 days. Continued use for a year maintained these benefits, reducing symptoms and enhancing eye health. Flarex, another eye drop, reduces eye swelling and quickly eased inflammation for most users, sometimes within two weeks. In this trial, participants will receive a combination of Vevye and Flarex to relieve dry eye disease by addressing both dryness and swelling.¹³⁴⁵⁶